84354 Federal Register / Vol. 89, No. 204 / Tuesday, October 22, 2024 / Notices 

1 21 CFR 201.56(a) and (d) and 201.57(c)(8). This 

guidance applies to drugs, including biological 

products that are regulated as drugs. For the 

purpose of this guidance, ‘‘drug product’’ or ‘‘drug’’ 

will be used to refer to human prescription drug 

and biological products that are regulated as drugs. 

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

You may submit comments on any 

guidance at any time (see 21 CFR 

10.115(g)(5)). 

Submit written requests for single 

copies of this guidance to the Division 

of Drug Information, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10001 New 

Hampshire Ave., Hillandale Building, 

4th Floor, Silver Spring, MD 20993– 

0002, or the Office of Communication, 

Outreach and Development, Center for 

Biologics Evaluation and Research 

(CBER), Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 71, 

Rm. 3128, Silver Spring, MD 20993– 

0002. Send one self-addressed adhesive 

label to assist that office in processing 

your requests. The guidance may also be 

obtained by mail by calling CBER at 1– 

800–835–4709 or 240–402–8010. See 

the SUPPLEMENTARY INFORMATION section 

for electronic access to the guidance 

document. 

FOR FURTHER INFORMATION CONTACT: 

Joseph Grillo, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Silver Spring, MD 

20993–0002, 301–796–0591; or James 

Myers, Center for Biologics Evaluation 

and Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 71, Rm. 7301, Silver Spring, 

MD 20993–0002, 240–402–7911. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

a draft guidance for industry entitled 

‘‘Drug Interactions Section of Labeling 

for Human Prescription Drug and 

Biological Products—Content and 

Format.’’ The draft guidance is intended 

to assist applicants in developing the 

DRUG INTERACTIONS section of the 

Prescribing Information labeling as 

described in FDA regulations for the 

content and format of labeling for 

human prescription drug and biological 

products.1

Prescription drug labeling must 

contain a summary of the essential 

information necessary for safe and 

effective use of the drug and is a 

primary tool for FDA to communicate 

drug interaction information to 

healthcare practitioners. Effective 

communication of drug interaction 

information informs the optimal use of 

the drug and the healthcare 

practitioner’s clinical decision-making 

(e.g., prescribing decisions or 

management instructions). 

The purpose of this guidance is to 

provide recommendations on what 

information to include in, and how to 

present and organize the information 

within, the DRUG INTERACTIONS 

section of prescription drug labeling to 

enhance communication of clinically 

significant drug interactions and 

facilitate the safe and effective use of 

prescription drugs by healthcare 

practitioners. This guidance also 

provides illustrative examples of the 

content and format of drug interaction 

information in prescription drug 

labeling. 

In addition, the guidance includes an 

FDA website (https://www.fda.gov/ 

CYPandTransporterInteractingDrugs) as 

one resource that health care 

practitioners can use to view examples 

of clinical substrates, inhibitors, and 

inducers of Cytochrome P–450 (CYP) 

enzymes and substrates and inhibitors 

of transporters. FDA is seeking input 

regarding the utility of this website as a 

resource that health care practitioners 

can reference to find examples of 

clinical substrates, inhibitors, and 

inducers of CYP enzymes and substrates 

and inhibitors of transporters. FDA is 

also seeking input on ways to describe 

drug interactions in labeling, 

specifically when drugs have numerous, 

clinically relevant drug interactions 

(e.g., azole antimycotics) that require 

listing many interactions. In addition, 

FDA is seeking input on ways to 

describe complex drug-interaction 

scenarios, including but not limited to: 

• Concurrent inhibition of an enzyme 

and a transporter by a drug; 

• Concurrent inhibition and 

induction of a drug’s metabolic pathway 

by one or more enzymes; 

• Increased inhibition of drug 

elimination by use of inhibitors of more 

than one enzyme that metabolizes the 

drug; 

• Inhibition of an enzyme other than 

the genetic polymorphic enzyme in poor 

metabolizers taking a substrate 

metabolized by both enzymes; 

• Effect of enzyme/transporter 

inhibitors in subjects with organ 

impairment; and 

• Two drugs acting as both 

precipitant and object of a drug 

interaction. 

The draft guidance, when finalized, 

will represent the current thinking of 

FDA on ‘‘Drug Interaction Information 

in Human Prescription Drug and 

Biological Product Labeling.’’ It does not 

establish any rights for any person and 

is not binding on FDA or the public. 

You can use an alternative approach if 

it satisfies the requirements of the 

applicable statutes and regulations. 

II. Paperwork Reduction Act of 1995 

While this guidance contains no 

collection of information, it does refer to 

previously approved FDA collections of 

information. The previously approved 

collections of information are subject to 

review by the Office of Management and 

Budget (OMB) under the Paperwork 

Reduction Act of 1995 (PRA) (44 U.S.C. 

3501–3521). The collections of 

information in 21 CFR parts 314 and 

601 are approved under OMB control 

numbers 0910–0001 and 0910–0338, 

respectively. The collections of 

information in 21 CFR parts 201.56 and 

201.57 have been approved under OMB 

control number 0910–0572. 

III. Electronic Access 

Persons with access to the internet 

may obtain the draft guidance at https:// 

www.regulations.gov, https://

www.fda.gov/drugs/guidancecompliance-regulatory-information/ 

guidances-drugs, https://www.fda.gov/ 

vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics/biologics-guidances, or https:// 

www.fda.gov/regulatory-information/ 

search-fda-guidance-documents. 

Dated: October 16, 2024. 

Eric Flamm, 

Acting Associate Commissioner for Policy. 

[FR Doc. 2024–24442 Filed 10–21–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Notice of Request for Public 

Comments on Draft Recommendations 

for the HRSA-Supported Women’s 

Preventive Services Guidelines 

Relating to Screening and Counseling 

for Intimate Partner and Domestic 

Violence, Breast Cancer Screening for 

Women at Average Risk, and Patient 

Navigation for Breast and Cervical 

Cancer Screening 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 204 / Tuesday, October 22, 2024 / Notices 84355 

SUMMARY: This notice seeks comment on 

draft recommendations for the HRSAsupported Women’s Preventive Services 

Guidelines (‘‘Guidelines’’) relating to 

Screening and Counseling for Intimate 

Partner and Domestic Violence, Breast 

Cancer Screening for Women at Average 

Risk, and Patient Navigation for Breast 

and Cervical Cancer Screening. These 

draft recommendations have been 

developed by the Women’s Preventive 

Services Initiative (WPSI), through 

which clinicians, academics, and expert 

health professionals develop draft 

recommendations for HRSA’s 

consideration. Under applicable law, 

non-grandfathered group health plans 

and health insurance issuers must 

include coverage, without cost sharing, 

for certain preventive services, 

including those provided for in the 

HRSA-supported Guidelines. The 

Departments of Labor, HHS, and 

Treasury have issued regulations and 

policy guidance which describe how 

group health plans and health insurance 

issuers apply the coverage requirements. 

DATES: Members of the public are 

invited to provide written comments no 

later than November 21, 2024. All 

comments received on or before this 

date will be reviewed and considered by 

WPSI and provided for further 

consideration by HRSA in determining 

the recommended updates that it will 

support. 

ADDRESSES: Members of the public who 

wish to provide comments can do so by 

accessing the public comment web page 

at https://www.womenspreventive

health.org/. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Sherman, HRSA, Maternal 

and Child Health Bureau, telephone 

(301) 443–8283, email: wellwomancare@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: Under 

section 1001(5) of the Patient Protection 

and Affordable Care Act, Public Law 

111–148, which added section 2713 to 

the Public Health Service Act, 42 U.S.C. 

300gg–13, the preventive care and 

screenings set forth in the HRSASupported Women’s Preventive Services 

Guidelines are required to be covered 

without cost-sharing by certain group 

health plans and health insurance 

issuers. HRSA established the 

Guidelines in 2011 based on expert 

recommendations by the Institute of 

Medicine, now known as the National 

Academy of Medicine. 

Since 2016, HRSA has funded 

cooperative agreements to support WPSI 

to convene clinicians, academics, and 

consumer-focused health professional 

organizations to conduct a rigorous 

review of current scientific evidence, 

solicit and consider public input, and 

make recommendations to HRSA 

regarding updates to the Guidelines to 

improve women’s health across the 

lifespan. HRSA determines whether to 

support, in whole or in part, the 

recommended updates to the 

Guidelines. WPSI consists of an 

Advisory Panel and two expert 

committees, the Multidisciplinary 

Steering Committee and the 

Dissemination and Implementation 

Steering Committee, which are 

comprised of a broad coalition of 

organizational representatives who are 

experts in disease prevention and 

women’s health issues. With oversight 

by the Advisory Panel, and with input 

from the Multidisciplinary Steering 

Committee, WPSI examines the 

evidence to develop new (and update 

existing) recommendations for women’s 

preventive services. WPSI’s 

Dissemination and Implementation 

Steering Committee takes HRSAapproved recommendations and 

disseminates them through the 

development of implementation tools 

and resources for both patients and 

practitioners. 

WPSI bases its recommended updates 

to the Guidelines on review and 

synthesis of existing clinical guidelines 

and new scientific evidence, following 

the National Academy of Medicine 

standards for establishing foundations 

for and rating strengths of 

recommendations, articulation of 

recommendations, and external reviews. 

Additionally, HRSA requires that WPSI 

incorporate processes to assure 

opportunity for public comment, 

including participation by patients and 

consumers, in the development of its 

recommendations to update the 

Guidelines. This notice seeks comment 

on three Guidelines: 

(1) Screening and Counseling for 

Intimate Partner and Domestic Violence 

WPSI recommends updating the 

existing Guideline for Screening and 

Counseling for Interpersonal and 

Domestic Violence. The current 

Guideline for Screening and Counseling 

for Interpersonal and Domestic Violence 

is: ‘‘WPSI recommends screening 

adolescents and women for 

interpersonal and domestic violence, at 

least annually, and, when needed, 

providing, or referring for initial 

intervention services. Interpersonal and 

domestic violence includes physical 

violence, sexual violence, stalking and 

psychological aggression (including 

coercion), reproductive coercion, 

neglect, and the threat of violence, 

abuse, or both. Intervention services 

include, but are not limited to, 

counseling, education, harm reduction 

strategies, and referral to appropriate 

supportive services.’’ 

The proposed updated Guideline for 

Screening and Counseling for Intimate 

Partner and Domestic Violence is: ‘‘The 

Women’s Preventive Services Initiative 

recommends screening adolescent and 

adult women for intimate partner and 

domestic violence, at least annually, 

and, when needed, providing or 

referring to intervention services. 

Intimate partner and domestic violence 

includes physical violence, sexual 

violence, stalking and psychological 

aggression (including coercion), 

reproductive coercion, neglect, and the 

threat of violence, abuse, or both. 

Intervention services include, but are 

not limited to, counseling, education, 

harm reduction strategies, and 

appropriate supportive services.’’ 

Background 

WPSI recommends several updates to 

the language of this Guideline. The first 

change is a revision to the title of the 

Guideline from ‘‘Interpersonal and 

Domestic Violence’’ to ‘‘Intimate Partner 

and Domestic Violence.’’ This change to 

the title was made to be consistent with 

language generally used in the clinical 

setting and the more commonly used 

term of ‘‘intimate partner violence’’ in 

the medical field. Corresponding 

revisions to change references from 

‘‘interpersonal’’ to ‘‘intimate partner’’ 

have been made throughout the text of 

the recommendation. WPSI also 

recommends adding the word ‘‘adult’’ 

prior to ‘‘women’’ in the 

recommendation, to clarify that both 

adolescent and adult women are 

included in the screening and 

counseling guidance. The words 

‘‘referral to’’ were removed from the last 

sentence to assist with clarity on the 

meaning of ‘‘intervention services.’’ 

Comments are sought on these proposed 

updates. 

(2) Breast Cancer Screening for Women 

at Average Risk 

WPSI is recommending updating the 

existing Guideline for Breast Cancer 

Screening for Average-Risk Women. The 

current guideline for Breast Cancer 

Screening for Average-Risk Women is: 

‘‘WPSI recommends that average-risk 

women initiate mammography 

screening no earlier than age 40 and no 

later than age 50. Screening 

mammography should occur at least 

biennially and as frequently as 

annually. Screening should continue 

through at least age 74 and age alone 

should not be the basis to discontinue 

screening. 


ddrumheller on DSK120RN23PROD with NOTICES1
84356 Federal Register / Vol. 89, No. 204 / Tuesday, October 22, 2024 / Notices 

1Nelson HD, O’Meara ES, Kerlikowske K, Balch 

S, Miglioretti D. Factors Associated With Rates of 

False-Positive and False-Negative Results From 

Digital Mammography Screening: An Analysis of 

Registry Data. Ann Intern Med. 2016 Feb 

16;164(4):226–35. doi: 10.7326/M15–0971. Epub 

2016 Jan 12. PMID: 26756902; PMCID: 

PMC5091936. 

2Beach ML, Flood AB, Robinson CM, et al. Can 

language-concordant prevention care managers 

improve cancer screening rates? Cancer Epidemiol 

Biomarkers Prev. 2007;16(10):2058–64. doi: 

10.1158/1055–9965.EPI–07–0373. PMID: 17932353. 3Thompson B, Carosso EA, Jhingan E, et al. 

Results of a randomized controlled trial to increase 

cervical cancer screening among rural Latinas. 

Cancer. 2017;123(4):666–74. doi: 10.1002/ 

cncr.30399. PMID: 27787893. 

These screening recommendations are 

for women at average risk of breast 

cancer. Women at increased risk should 

also undergo periodic mammography 

screening, however, recommendations 

for additional services are beyond the 

scope of this recommendation.’’ 

The proposed updated Guideline for 

Breast Cancer Screening for Women at 

Average Risk is: ‘‘The Women’s 

Preventive Services Initiative 

recommends that women at average-risk 

of breast cancer initiate mammography 

screening no earlier than age 40 and no 

later than age 50. Screening 

mammography should occur at least 

biennially and as frequently as 

annually. Women may require 

additional imaging to complete the 

screening process or to address findings 

on the initial screening mammography. 

If additional imaging (e.g., MRI, 

ultrasound, mammography) and 

pathology exams are indicated, those 

services are also recommended to 

complete the screening process for 

malignancies. Screening should 

continue through at least age 74 and age 

alone should not be the basis to 

discontinue screening. 

‘‘Women at increased risk should also 

undergo periodic mammography 

screening, however, recommendations 

for additional services are beyond the 

scope of this recommendation.’’ 

Background 

WPSI recommends several updates to 

the language of this Guideline. The first 

change is a revision to the title from 

‘‘Breast Cancer Screening for AverageRisk Women’’ to ‘‘Breast Cancer 

Screening for Women at Average Risk.’’ 

This change to the title was made to be 

consistent with changes recommended 

for the first sentence of this Guideline 

and to use person-first language that 

puts the individual before the diagnosis 

or screening modality. WPSI 

recommends updates to the first 

sentence of this Guideline, replacing the 

phrase ‘‘average-risk women’’ with 

‘‘women at average-risk for breast 

cancer’’ to clarify that the target 

population for this recommendation is 

specific to breast cancer. 

Two new sentences were added to 

follow the first sentence: ‘‘Women may 

require additional imaging to complete 

the screening process or to address 

findings on the initial screening 

mammography. If additional imaging 

(e.g., MRI, ultrasound, mammography) 

and pathology exams are indicated, 

those services are also recommended to 

complete the screening process for 

malignancies.’’ These modifications 

address the circumstances where initial 

mammography screening for women at 

average risk for breast cancer is 

incomplete or additional action is 

necessary to fully complete breast 

cancer screening for the individual. 

Specifically, these two sentences were 

added to ensure completed screening for 

women who were initially screened for 

breast cancer and need additional 

screening tests. Imaging in addition to 

initial screening mammography, such as 

special mammography views, 

ultrasound, or MRI, may be needed in 

individual clinical situations when 

clinicians require an enhanced view of 

breast tissue to differentiate normal 

from abnormal findings. A tissue biopsy 

may also need to be performed to 

determine whether abnormal findings 

are cancer, normal tissue, or other type 

of lesion. In an analysis of 405,191 

women in the Breast Cancer 

Surveillance Consortium breast imaging 

registry who underwent digital 

mammography, 40,557 (10 percent) 

were recommended for additional 

imaging, and 6,628 (1.6 percent) were 

recommended for biopsy.1

WPSI also has recommended 

removing the following sentence from 

the existing Guideline, ‘‘These screening 

recommendations are for women at 

average risk of breast cancer’’ as this 

information is now included in the 

revised first sentence of the updated 

Guideline. Comments are sought on 

these proposed updates. 

(3) Patient Navigation for Breast and 

Cervical Cancer Screening 

WPSI is proposing a new Guideline 

for Patient Navigation for Breast and 

Cervical Cancer Screening, as follows: 

‘‘The Women’s Preventive Services 

Initiative (WPSI) recommends patient 

navigation services for breast and 

cervical cancer screening and follow-up, 

as relevant, to increase utilization of 

screening recommendations based on an 

assessment of the patient’s need for 

navigation services. Patient navigation 

services involve person-to-person (e.g., 

in-person, virtual, hybrid models) 

contact with the patient. Components of 

patient navigation services should be 

individualized. 

Services include, but are not limited 

to, person-centered assessment and 

planning, health care access and health 

system navigation, referrals to 

appropriate support services (e.g., 

language translation, transportation, and 

social services), and patient education.’’ 

Background 

WPSI has submitted a new draft 

clinical recommendation on Patient 

Navigation for Breast and Cervical 

Cancer Screening for review, comment, 

and consideration. Recent clinical 

research has found consistent 

effectiveness of patient navigation 

services for breast and cervical cancer 

screening in reducing barriers to 

screening and follow-up care, resulting 

in higher screening rates. Breast cancer 

screening rates were 14.1% higher for 

35,752 patients randomized to patient 

navigation services versus usual care or 

active controls in a WPSI meta-analysis 

of 33 randomized control trials based in 

U.S. health care settings. The same 

meta-analysis showed rates for cervical 

cancer screening and follow-up were 

higher with patient navigation by 

15.7%, based on 22 randomized control 

trials with 12,221 participants. 

Research suggests that patient 

navigation is effective across a wide 

range of health care settings and 

provider types. In one study included in 

WPSI’s meta-analysis, prevention care 

managers working in federally qualified 

health centers (FQHCs) who employed 

patient navigation services increased 

breast cancer screening among patients 

without a mammogram in the past 18 

months to 68% compared to 57% for 

patients in usual care.2 Another study 

included in the meta-analysis analyzed 

rural Latinas who had not previously 

undergone recommended screening. 

The study found that enhanced 

education efforts increased cervical 

cancer screening to 53.4% as compared 

to 34% in usual care without these 

navigation services.3

Research also shows that reducing 

barriers to screening and follow-up care 

can result in earlier identification of 

breast and cervical cancer, enabling 

patients to enter into treatment earlier, 

preventing progression of these 

conditions, improving health outcomes 

and survival rates, and ultimately can 

reduce disparities in cancer morbidity 

and mortality. In the meta-analysis, 

patient navigation services increased 

screening and follow-up for breast 

cancer by 10.2% in populations 

described as low-income. Based on this 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 204 / Tuesday, October 22, 2024 / Notices 84357 

clinical evidence that supports the 

preventive benefits of patient navigation 

services for breast and cervical cancer 

screening, WPSI recommends adding 

these patient navigation services to the 

Guidelines. Comments are sought on 

this proposed Guideline. 

Members of the public can view the 

complete updated and new draft clinical 

recommendations, as well as the 

implementation considerations and 

research recommendations (which are 

not part of the Guidelines), by accessing 

WPSI’s web page at https://

www.womenspreventivehealth.org/. 

Carole Johnson, 

Administrator. 

[FR Doc. 2024–24445 Filed 10–21–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Training and Primary Care Medicine 

and Dentistry 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Training in Primary Care 

Medicine and Dentistry (ACTPCMD or 

Committee) will hold one additional 

public meeting in the 2024 calendar 

year. Information about ACTPCMD, 

agendas, and materials for these 

meetings can be found on the 

ACTPCMD website at https://

www.hrsa.gov/advisory-committees/ 

primarycare-dentist/meetings. This 

notice is consistent with the information 

about ACTPCMD’s calendar year 2024 

meetings found in the Federal Register 

notice dated May 15, 2024, Meeting of 

the Advisory Committee on Training 

and Primary Care Medicine and 

Dentistry. 

DATES: The ACTPCMD meeting will be 

held on: 

• November 15, 2024, 10:00 a.m.–5:00 

p.m. Eastern Time. 

ADDRESSES: This meeting will be held 

by teleconference and/or a video 

conference platform. For updates on 

how the meeting will be held, visit the 

ACTPCMD website 20 days before the 

date of the meeting, where instructions 

for joining the meeting will be posted. 

For meeting information updates, go to 

the ACTPCMD website meeting page at 

https://www.hrsa.gov/advisorycommittees/primarycare-dentist/ 

meetings. 

FOR FURTHER INFORMATION CONTACT: 

Shane Rogers, Designated Federal 

Officer, Division of Medicine and 

Dentistry, Bureau of Health Workforce, 

HRSA, 5600 Fishers Lane, Room 

15N102, Rockville, Maryland 20857; 

301–443–5260; or SRogers@hrsa.gov. 

SUPPLEMENTARY INFORMATION: 

ACTPCMD provides advice and 

recommendations to the Secretary of 

Health and Human Services on policy, 

program development, and other 

matters of significance concerning the 

activities under Section 747 of Title VII 

of the Public Health Service (PHS) Act, 

as it existed upon the enactment of 

Section 749 of the PHS Act in 1998. 

ACTPCMD prepares an annual report 

describing the activities of the 

committee, including findings and 

recommendations made by the 

committee concerning the activities 

under Section 747, as well as training 

programs in oral health and dentistry. 

The annual report is submitted to the 

Secretary of Health and Human Services 

as well as the Chair and ranking 

members of the Senate Committee on 

Health, Education, Labor and Pensions 

and the House of Representatives 

Committee on Energy and Commerce. 

ACTPCMD also develops, publishes, 

and implements performance measures 

and guidelines for longitudinal 

evaluations of programs authorized 

under Title VII, Part C of the PHS Act, 

and recommends appropriation levels 

for programs under this Part. 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

For the November 15th meeting, agenda 

items may include, but are not limited 

to, discussion of recommendations for 

the committee’s 23rd report, as well as 

exploratory topic discussions for the 

committee’s 24th report. Refer to the 

ACTPCMD website listed above for all 

current and updated information 

concerning the November 15th 

ACTPCMD meeting, including the 

agenda and meeting materials that will 

be posted 20 calendar days before the 

meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting. Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to the 

ACTPCMD should be sent to Shane 

Rogers using the contact information 

above at least 5 business days before the 

meeting date. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Shane 

Rogers using the contact information 

listed above at least 10 business days 

before the meeting they wish to attend. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–24328 Filed 10–21–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission to OMB for 

Review and Approval; Public Comment 

Request; Black Lung Clinics Program 

Performance Measures 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, 

HRSA submitted an Information 

Collection Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public during the review and 

approval period. OMB may act on 

HRSA’s ICR only after the 30-day 

comment period for this notice has 

closed. 

DATES: Comments on this ICR should be 

received no later than November 21, 

2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email 

Joella Roland, the HRSA Information 

Collection Clearance Officer, at 

paperwork@hrsa.gov or call (301) 443– 

3983. 

SUPPLEMENTARY INFORMATION: 


ddrumheller on DSK120RN23PROD with NOTICES1